GT Biopharma (GTBP) Notes Payables (2013 - 2024)
GT Biopharma (GTBP) posted quarterly Notes Payables of $394000.0 for Q1 2024, down 86.53% year-over-year from $2.9 million in Q2 2023, and down 62.55% quarter-over-quarter from $1.1 million in Q4 2023.
GT Biopharma (GTBP) Notes Payables (2013 - 2024) Analysis & Trends
GT Biopharma (GTBP) has reported Notes Payables for 7 consecutive years, with $394000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Notes Payables fell 86.53% year-over-year to $394000.0; the TTM figure through Mar 2024 stood at $394000.0 (down 86.53% YoY), while the FY2023 annual figure was $1.1 million, up 5436.84% from the prior year.
- Notes Payables retreated to $394000.0 in Q1 2024 per GTBP's latest filing, from $1.1 million in the prior quarter.
- Across five years, Notes Payables topped out at $2.9 million in Q1 2023 and bottomed at $19000.0 in Q4 2022.
- Historically, Notes Payables has averaged $667142.9 across 5 years, with a median of $373000.0 in 2020.
- Annual changes were most pronounced in 2023 — Notes Payables jumped 5436.84% — and 2024, when it sank 86.53%.
- GT Biopharma's Notes Payables stood at $384000.0 in 2020, then tumbled by 64.06% to $138000.0 in 2021, then sank by 86.23% to $19000.0 in 2022, then surged by 5436.84% to $1.1 million in 2023, then plunged by 62.55% to $394000.0 in 2024.
- Business Quant data shows GTBP's Notes Payables at $394000.0 in Q1 2024, $1.1 million in Q4 2023, and $1.1 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 394,000.00 |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 1.54 Mn |
| Mar 31, 2023 | 2.93 Mn |
| Dec 31, 2022 | 19,000.00 |
| Sep 30, 2022 | 57,000.00 |
| Jun 30, 2022 | 115,000.00 |
| Mar 31, 2022 | 120,000.00 |
| Dec 31, 2021 | 138,000.00 |
| Sep 30, 2021 | 340,000.00 |
| Jun 30, 2021 | 842,000.00 |
| Mar 31, 2021 | 362,000.00 |
| Dec 31, 2020 | 384,000.00 |
| Dec 31, 2018 | 100,000.00 |
| Mar 31, 2013 | 1,000.00 |